Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Ureteral Neoplasms × pembrolizumab × Clear all

Phase

Phase 2 2 Phase 1 2 Phase 4 1 Phase 3 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 84 Carcinoma, Non-Small-Cell Lung 75 Lung Neoplasms 20 Melanoma 17 Squamous Cell Carcinoma of Head and Neck 16 Triple Negative Breast Neoplasms 11 Stomach Neoplasms 10 Head and Neck Neoplasms 10 Carcinoma, Renal Cell 10 Breast Neoplasms 10 Carcinoma 9 Neoplasms 8 Neoplasm Metastasis 8 Endometrial Neoplasms 7 Urinary Bladder Neoplasms 6 Carcinoma, Hepatocellular 6 Colorectal Neoplasms 5 Carcinoma, Transitional Cell 5 Uterine Cervical Neoplasms 4 Prostatic Neoplasms 4 Esophageal Neoplasms 4 Cholangiocarcinoma 4 Thoracic Neoplasms 3 Skin Neoplasms 3 Respiratory Tract Neoplasms 3 Respiratory Tract Diseases 3 Ovarian Neoplasms 3 Neoplasms by Site 3 Lung Diseases 3 Gallbladder Neoplasms 3

Interventions

Specimen Handling 2 Magnetic Resonance Spectroscopy 2 vinflunine 1 pembrolizumab 1 enfortumab vedotin 1 cabozantinib 1 avelumab 1 Watchful Waiting 1 Vitamin B 12 1 Platinum 1 Pemetrexed 1 Paclitaxel 1 Observation 1 Morphine 1 Immunoglobulin G 1 Gemcitabine 1 Folic Acid 1 Docetaxel 1 Disulfides 1 Dexamethasone 1 Cystoscopy 1 Cisplatin 1 Calcium Dobesilate 1 Bupivacaine 1 Bevacizumab 1 1,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03244384 2026-03-19

AMBASSADOR

National Cancer Institute (NCI)

Phase 3 Active not recruiting

Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡